mucomyst freyðitafla 200 mg
viatris aps - acetylcysteinum inn - freyðitafla - 200 mg
epclusa
gilead sciences ireland uc - sofosbuvir, velpatasvir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 og 5.
harvoni
gilead sciences ireland uc - ledipasvir, sofosbuvir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 og 5. fyrir lifrarbólgu c veira (hcv) arfgerð-sérstakur starfsemi sjá kafla 4. 4 og 5.
vosevi
gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (sjá kafla 4. 2, 4. 4 og 5.
fortum stungulyfs-/innrennslisstofn, lausn 2 g
sandoz a/s - ceftazidimum inn - stungulyfs-/innrennslisstofn, lausn - 2 g
fortum stungulyfsstofn, lausn 1 g
sandoz a/s - ceftazidimum inn - stungulyfsstofn, lausn - 1 g
sefitude (quietude) húðuð tafla 445 mg
florealis ehf. - valerian root dry extract (3-6:1), ethanol 70 %(v/v) - húðuð tafla - 445 mg
meropenem sun stungulyfs-/innrennslisstofn, lausn 1 g
sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 1 g
meropenem wh (meropenem w&h) stungulyfs-/innrennslisstofn, lausn 500 mg
williams & halls ehf. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 500 mg
meropenem sun stungulyfs-/innrennslisstofn, lausn 500 mg
sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 500 mg